The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 25, 2025

Filed:

Nov. 26, 2021
Applicant:

Beijing Baheal Chengchuang Pharmaceutical Research and Development Co., Ltd., Beijing, CN;

Inventors:

Yimin Cui, Beijing, CN;

Xiaocong Pang, Beijing, CN;

Xu He, Beijing, CN;

Yanlun Gu, Beijing, CN;

Zhenming Liu, Beijing, CN;

Song Song, Beijing, CN;

Xia Zhao, Beijing, CN;

Ying Zhou, Beijing, CN;

Qian Xiang, Beijing, CN;

Junling Zhang, Beijing, CN;

Ran Xie, Beijing, CN;

Xiaojiao Sun, Beijing, CN;

Zhuo Zhang, Beijing, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 231/56 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 231/56 (2013.01); A61P 35/00 (2018.01);
Abstract

An indazole hydrazide compound, as represented in formula (I); wherein, R is selected from substituted alkyl, substituted alkenyl and substituted phenyl; substituent in the substituted alkyl and substituted alkenyl includes phenyl and/or substituted phenyl; R′ is selected from H and alkyl. Compared with the prior art, the above indole hydrazide compound can be used as integrin avβ3 receptor antagonist. Besides, it has obvious anti-prostate cancer activity and has a significant inhibitory effect on enzalutamide-resistant cell lines. In addition, the above-mentioned compound has obvious anti-tumor angiogenesis activity and can be used in the preparation of anti-tumor angiogenesis drugs to inhibit tumor angiogenesis.


Find Patent Forward Citations

Loading…